Listen to this article · 7 min listen

The path to innovation in healthcare AI is not always linear. Sometimes, a cleared trail and promising initial results still lead to an unexpected end. For investors mapping the market, the failure of a company like Pear Therapeutics offers more instructive lessons than the unqualified success of others, precisely because its trajectory leaves a visible paper trail of what worked and, critically, what did not hold. This record, anchored in patient engagement and regulatory clearance material, provides a post-mortem read that highlights an important distinction: a product can navigate the most stringent regulatory hurdles and publish compelling early data, yet still falter when confronted with the realities of sustained user adoption in delivery.

The Cleared Route: Regulatory Wins and Published Promise

Pear Therapeutics, a pioneer in prescription digital therapeutics (PDTs), secured significant regulatory milestones. Its lead product, reSET, received FDA 510(k) clearance in 2017 for substance use disorder, followed by reSET-O in 2018 for opioid use disorder. These clearances were not trivial. They marked a critical moment for SaMD, demonstrating a viable pathway for software to be recognized as a medical device requiring a prescription. This regulatory success was proof of the company’s ability to navigate the FDA’s CDRH (Center for Devices and Radiological Health) processes, establishing a framework that many subsequent digital health companies would look to emulate. Beyond regulatory validation, Pear also published results in peer-reviewed journals, indicating the clinical efficacy of its digital interventions. Studies detailed how these PDTs could improve abstinence rates and retention in treatment programs, providing the evidence base necessary for physician adoption and, theoretically, payer reimbursement. These published results, often in conjunction with traditional therapies, underscored the potential for digital tools to augment existing care paradigms, suggesting a future where software could play a central role in chronic disease management. The combination of FDA clearance and published clinical data presented a compelling narrative of innovation and impact.

The Engagement Gap: Where the Trail Frayed

Despite these early successes, the commercial journey for Pear Therapeutics proved challenging. The instructive read here is that the failure post-mortem starts at engagement, not at technology or even initial regulatory approval. While the technology was cleared and results published, the sustained patient engagement necessary for real-world clinical impact and commercial viability proved elusive. Patient engagement, in the context of digital therapeutics, refers to the consistent and meaningful interaction of patients with the prescribed digital intervention over time. It is not merely about initial downloads or activations, but about continuous use that translates into therapeutic benefit. For Pear, and for many digital health solutions, the challenge lay in maintaining this engagement beyond the initial novelty or mandated use. The data points from the recorded set, specifically those pertaining to patient engagement, reveal that the cleared path alone does not guarantee commercial survival if patients do not consistently use the product as intended. Without sustained engagement, even a clinically effective and FDA-cleared product cannot deliver its intended outcomes at scale, thereby undermining its value proposition to providers and payers alike.

Comparators: Omada Health and Virta Health

To understand the nuances of Pear’s experience, it is useful to consider it alongside other digital health innovators like Omada Health and Virta Health. These companies, while operating in different therapeutic areas (chronic disease management and diabetes reversal, respectively), also navigated regulatory field and sought to demonstrate clinical impact through digital interventions. Omada Health, for instance, focused on behavior change programs for chronic conditions such as type 2 diabetes and hypertension. Its model emphasized coaching, peer support, and personalized digital content to drive sustained engagement and measurable health outcomes. Omada Health completed an initial public offering (IPO) on June 9, 2025, and reported strong financial results in Q2 2026, with revenue up 43% year-over-year and positive net income. Virta Health similarly leveraged a digital platform to deliver nutritional therapy and coaching for type 2 diabetes reversal, often showing impressive outcomes in blood sugar control and medication reduction. Virta Health reached profitability in Q3 2026 and was recognized as one of the World’s Top HealthTech Companies of 2026 by TIME magazine. Both companies have invested heavily in demonstrating not just efficacy, but also the ability to maintain patient adherence and engagement over extended periods, understanding that these factors are critical for achieving real-world health improvements and securing payer contracts. The patient engagement records for these companies, when available, often highlight strategies and outcomes that speak to more sustained user interaction, a stark contrast to the challenges faced by Pear Therapeutics in maintaining consistent use. The common thread across these innovators, successful or otherwise, is the critical role of patient engagement as a signal for commercial viability. FDA CDRH material shows how far a cleared path can take a product before the commercial question arrives, but it does not answer that question. The regulatory body assesses safety and efficacy, not long-term adherence or market penetration.

The Post-Mortem Question for Investors

For investors studying market maps and potential failure cases, the experience of Pear Therapeutics, alongside the comparative trajectories of Omada Health and Virta Health, crystallizes a critical post-mortem question: Does the engagement record hold in delivery? A product may secure a 510(k) clearance or even a De Novo classification FDA De Novo guidance and publish compelling real-world evidence (RWE) FDA RWE framework in reputable journals. It may even boast a strong data moat built from proprietary datasets. Yet, if the patient engagement data reveals a significant drop-off in sustained use, the commercial prospects become severely constrained. This is not to diminish the importance of regulatory clearance or clinical validation. These are non-negotiable foundations for any credible healthcare AI company. However, they are insufficient on their own. The instructive read is that the commercial success of digital health solutions, particularly SaMD, hinges on their ability to integrate smoothly into patients’ lives and drive consistent behavioral change or adherence. Without this, even the most innovative technology, backed by strong clinical data and regulatory approval, risks becoming a zombie company, unable to scale or achieve its intended impact. In the end, Pear Therapeutics filed for Chapter 11 bankruptcy in April 2023, and its assets, including reSET and reSET-O, were subsequently acquired by other entities, with PursueCare relaunching the products in September 2024. Investors must scrutinize not just the initial efficacy, but the mechanisms and evidence for sustained patient engagement, understanding that this is often the true arbiter of long-term market survival and impact.

Frequently Asked Questions

What was Pear Therapeutics’ primary regulatory achievement?

Pear Therapeutics secured significant regulatory milestones, including FDA 510(k) clearance for its lead product reSET in 2017 for substance use disorder and reSET-O in 2018 for opioid use disorder. These clearances demonstrated a viable pathway for software to be recognized as a medical device requiring a prescription.

Despite regulatory clearance, why did Pear Therapeutics fail commercially?

Pear Therapeutics failed commercially due to a lack of sustained patient engagement. While the technology was cleared and clinical results published, patients did not consistently use the product as intended over time, undermining its value proposition to providers and payers.

What critical factor, beyond regulatory approval, is essential for the commercial success of digital health products?

Beyond regulatory approval and published clinical data, sustained patient engagement is critical for the commercial success of digital health products. This refers to the consistent and meaningful interaction of patients with the prescribed digital intervention over time, which translates into therapeutic benefit and commercial viability.

How did successful digital health companies like Omada Health and Virta Health differ from Pear Therapeutics?

Omada Health and Virta Health, unlike Pear Therapeutics, invested heavily in demonstrating not just efficacy, but also the ability to maintain patient adherence and engagement over extended periods. Their models emphasized coaching, peer support, and personalized content to drive sustained user interaction, which proved critical for achieving real-world health improvements and securing payer contracts.